Purpose: In addition to becoming familiar with the life changing event of having a chronic illness and exploring its meaning in daily life, people with relapsing-remitting Multiple Sclerosis (RRMS) are faced with important decisions about immunomodulating treatment. Biomedical research on the use of Disease Modifying Therapies (DMTs) mostly focuses on adherence, conceptualized and understood as a behavioral act leading to a desired outcome. Less attention has been paid to the meaning for a person with RRMS of starting and continuing the use of DMTs. Studies on the experiences of people with RRMS taking orally administered DMTs are lacking. The aim of this phenomenological study was to examine the experiences of people with RRMS taking oral ...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...
Copyright © 2014 G. Di Battista et al. This is an open access article distributed under the Creative...
OBJECTIVE: The introduction of oral disease-modifying drugs (DMDs) in addition to the available, inj...
Purpose: In addition to becoming familiar with the life changing event of having a chronic illness a...
Physicians commonly advise patients to begin disease modifying therapies (DMT's) shortly after the e...
Background Physicians commonly advise patients to begin disease modifying therapies (DMT's) shortly ...
Abstract Background Besides coping with a disease with many uncertainties, people with relapsing-rem...
Introduction. Multiple sclerosis is an inflammatory demyelinating disease of the central nervous sys...
Introduction : People with Relapsing Remitting Multiple Sclerosis (RRMS) are increasingly included ...
OBJECTIVE: Disease-Modifying Treatments (DMTs) have contributed to a new clinical landscape for peop...
In this independent, multicenter, retrospective study, we investigated the short-term persistence to...
Background There are now large cohorts of people with relapsing-remitting multiple sclerosis (pwRRM...
Objective: Disease-Modifying Treatments (DMTs) have contributed to a new clinical landscape for peop...
Multiple Sclerosis (MS) is a neurological condition often characterised by its unpredictability, and...
textObjective: To examine reasons why Multiple Sclerosis (MS) patients may not be adherent to diseas...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...
Copyright © 2014 G. Di Battista et al. This is an open access article distributed under the Creative...
OBJECTIVE: The introduction of oral disease-modifying drugs (DMDs) in addition to the available, inj...
Purpose: In addition to becoming familiar with the life changing event of having a chronic illness a...
Physicians commonly advise patients to begin disease modifying therapies (DMT's) shortly after the e...
Background Physicians commonly advise patients to begin disease modifying therapies (DMT's) shortly ...
Abstract Background Besides coping with a disease with many uncertainties, people with relapsing-rem...
Introduction. Multiple sclerosis is an inflammatory demyelinating disease of the central nervous sys...
Introduction : People with Relapsing Remitting Multiple Sclerosis (RRMS) are increasingly included ...
OBJECTIVE: Disease-Modifying Treatments (DMTs) have contributed to a new clinical landscape for peop...
In this independent, multicenter, retrospective study, we investigated the short-term persistence to...
Background There are now large cohorts of people with relapsing-remitting multiple sclerosis (pwRRM...
Objective: Disease-Modifying Treatments (DMTs) have contributed to a new clinical landscape for peop...
Multiple Sclerosis (MS) is a neurological condition often characterised by its unpredictability, and...
textObjective: To examine reasons why Multiple Sclerosis (MS) patients may not be adherent to diseas...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...
Copyright © 2014 G. Di Battista et al. This is an open access article distributed under the Creative...
OBJECTIVE: The introduction of oral disease-modifying drugs (DMDs) in addition to the available, inj...